Second-Generation Diabetes Asset Launch: Immediately Commit to Full Go-to-Market, or First Run a Time-Boxed Regional and Access Evidence Gate?

Minerva judgment

Adopt a time-boxed, stoppable regional, segment, and access evidence gate to sequence the launch, since there is currently no jointly validated evidence supporting full commitment, and all three teams agree that any initial investment must be stoppable; this path preserves the competitive window while avoiding irreversible risk

Decision owner in the teaching simulationChair of the Asset Commercialization Committee, in an independent educational simulation

Human-controlled next action

The committee chair approves the design of a time-boxed regional evidence gate and requires the market access, commercial, and medical teams to jointly propose a minimum viable resource sequence and stop conditions within the gate deadline

What would reverse the recommendation

If evidence can be obtained to quantify the cost of the window (U1) and confirm it exceeds the cost of regional validation delay, or if the minimum viable investment sequence (U3) is clarified to show that full-commitment dependencies are manageable, the recommendation should reverse to accelerating full go-to-market

Illustration of a team reviewing decision cards around a meeting table — **Decision review illustration**
AI-generated illustration, not an actual customer scene or product screenshot. It does not demonstrate outcomes or imply endorsement.

Official public source

Charles River Associates · Developed go-to-market strategy for follow-on asset with blockbuster potential

Evidence and endorsement boundary：Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.

Inspect the evidence, then test your own decision context.

See the first-use journey Back to all 50 cases →

MINERVA DECISION READINESS REVIEW

Bring one decision you cannot afford to guess.

Minerva separates evidence, inference and unknowns, then shows options, the strongest objection and what would reverse the recommendation.

Start a Minerva Decision Readiness Review

Bring a real, de-identified decision. Google sign-in and product access are required; your plan and Decision Credits apply. You remain the decision-maker, and no email or external action is sent automatically.